Table 7.
Results of SCLC with bone metastases in previous studies
| Year/Country/Author | Study population | No. SCLC with BM | Findings of SCLC with BM | |
|---|---|---|---|---|
| Survival | Incidence of SREs | |||
| 2016 Korea Kang EJ et al [12]. |
ES-SCLC | 61 (BM at initial diagnosis) |
Median:4.13m; Poor prognostic factors: PS≥2; higher ALP |
34.4% |
| 2012, Japan K. Nakazawa et al [18] |
LS-SCLC+ ES-SCLC |
46 (BM at initial diagnosis); |
1 yr: 25% (without extraosseous metastases) | NR |
| 2018,Thailand Pruksakorn D et al.[8] | SCLC+NSCLC | 30 (BM at initial diagnosis) |
1 yr: 10.7% | NR |
| 2019, Brazil Silva GT et al [31] |
SCLC+NSCLC | 22 (BM at initial diagnosis /follow up) |
Median: 2.13m (with SREs), 8.57m (without SREs) p = 0.146 |
63.6% |
| 2014, Danish Cetin K et al.[32] |
SCLC+NSCLC | 340 (BM at initial diagnosis /follow up) |
NR | 50%. |
| 2014, Japan N. Katakami et al.[24] |
SCLC+NSCLC | 47 (BM at initial diagnosis /follow up) |
NR | 8.5% |
| 2016, Swiss (Conen K et al.) [33] |
SCLC | 92 (BM at initial diagnosis /follow up) |
NR | 18.4% (total) 8.7%(initial diagnosis) |
Abbreviations: BM=bone metastases; NR=not reported; m=months.